R&D
Research status
Future plan for research and development
| Name of project | Research period | Progress and future plan | Others |
|---|---|---|---|
| KDC-14-1 | 2014 - ongoing | - Pre-clinical trials (rodents, no rodents) completed. - IND application completed. - Phase 1, and Phase 2 clinical trials plan. |
Osteoporosis therapeutic agent |
| KDC-16-1 | 2016 - 2018 | - National project completed (December 2018) - Human application test (gastrointestinal health) completed. - Application for individual certification of material completed and health functional food. |
Certification of individual material in functional ingredient for gastrointestinal tract |
| KDC-17-2-1 | 2017 - ongoing | - Selection of valid substances completed. - Joint research plan with university hospital for ex vivo (mechanism research) and in vivo (animal test) studies. - Plan to apply for national project for pre-clinical and clinical trials. |
Anti-thrombotic combination agent |
| KDC-E17-1 | 2017 - ongoing | - Apply of controlled release technology through patent avoidance. - Formulation research ongoing, planned for release 2Q in 2020. |
Muscle relaxant |
| KDC-C17-2 | 2017 - ongoing | - Application of controlled release technology through patent avoidance. - Formulation research ongoing, planned for release 3Q in 2020. |
Anti-platelet agent |
| KDC-R18-1 | 2018 - ongoing | - In preparation for the dynamic stability test, scheduled for release 1Q in 2020. | Anti-Parkinson's disease drug |
| KDC-P18-2 | 2018 - ongoing | - Apply of controlled release technology and remaining system in the gastrointestinal track through patent avoidance. - Formulation research in progress, scheduled for release 4Q in 2022. |
Anti-epilepsy drug |
| KDC-D18-3 | 2018 - ongoing | - Apply of double delay release system through patent avoidance. - Formulation research in progress, scheduled for release 1Q in 2023. |
Anti-ulcer drug |
| Development of diabetic therapeutic substance | 2018 - ongoing | - Exploring candidate substances. | - |
| Development of muscle atrophy improvement agents | 2018 - ongoing | - Exploring candidate substances. | - |
| Classification | Department | Major responsibilities |
|---|---|---|
| Central Research Institute | Research planning Team | - Government project monitoring and new project application. - Progress management of government projects. - Identification of short-term, mid-term, and new project items. - Research document management and management of research support SOP. - Research budget management for government project. - Revision and management of research departments work standard. - Patent analysis and patent strategy establishment. - Patent filing, patent litigation, and litigation management. - Trademark filing, and trademark litigation management. - IP-R&D planning and patent portfolio design. - Establishment of intellectual property management system. |
| Formulation Research Team | - Review and analysis of patents and papers for improved drug candidates for formulation. - Research and validation of new formulation technologies to secure formulation efficacy. - Research and product development of new formulation source technologies. - Pre-formulation work for new substances and improved drug candidates. - Research on pharmaceutical process improvement and support for clinical trial drug production. |
|
| Pharmacology Research Team | - Evaluation of activity and efficacy of new substances. - Safety evaluation of active compounds. - Establishment and implementation of animal model to secure efficacy. - Establishment and implementation of in vitro/ in vivo evaluation system for PoC validation. - Lead research and conduct of non-clinical trial studies. - Toxicity studies for new drug candidates. |
Central Research Institute of Korean Drug Co. Ltd. has been awarded national project for their outstanding technology.
We established research infrastructure through collaboration with universities and national institutions (Kyung Buk national university medical school, Gachon university medical school, and Biotechnology Research institute), focusing on the development of natural, synthetic, and complex drug compounds.
| Category | Project name | Research title | Research period | Total research budget |
|---|---|---|---|---|
| Ministry of agriculture, food and rural affairs | Agricultural industry technology developmental service | Development and industrialization of osteoporosis treatment food and medicinal materials using common sate. | July 20, 2014 - July 28, 2019 (5 years) | Approximately 6.66 billion KRW |
| High Value food technology development project | Development and commercialization of natural ingredients for controlling atopic dermatitis aggravating factor. | Nov. 28, 2014 - Nov. 27, 2017 (3 years) | 1.2 billion KRW | |
| Development of novel functional food ingredients using portulaca extract. | July 7, 2016 - Dec. 31, 2018 (3 years) | Approximately 760 million KRW |
